p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Summary Cytotoxic chemotherapy for acute myeloid leukemia (AML) usually produces only temporary remissions, at the cost of significant toxicity and risk for death. One fundamental reason for treatment failure is that it is designed to activate apoptosis genes (eg., TP53) that may be unavailable because of mutation or deletion. Unlike deletion of apoptosis genes, genes that mediate cell cycle exit by differentiation are present in myelodysplastic syndrome (MDS) and AML cells but are epigenetically repressed: MDS/AML cells express high levels of key lineage-specifying transcription factors (TF). Mutation in these TF (eg., CEBPA) or their cofactors (eg., RUNX1) affect transactivation function and produce epigenetic repression of late-differentiation genes that antagonize MYC. Importantly, this aberrant epigenetic repression can be redressed clinically by depleting DNA methyltransferase 1 (DNMT1, a central component of the epigenetic network that mediates transcription repression) using the deoxycytidine analogue decitabine (DAC) at non-cytotoxic concentrations. The DNMT1 depletion is sufficient to trigger upregulation of late-differentiation genes and irreversible cell cycle exit by p53-independent differentiation mechanisms. Fortuitously, the same treatment maintains or increases self-renewal of normal hematopoietic stem cells (HSC), which do not express high levels of lineage-specifying TF. The biological rationale for this approach to therapy appears to apply to cancers other than MDS/AML also. DAC or 5-azacytidine dose and schedule can be rationalized to emphasize this mechanism of action, as an alternative or complement to conventional apoptosis-based oncotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation
Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G. M., Pasche, A.-C., Knabenhans, C., MacDonald, H. R., & Trumpp, A. (2004) · Genes & Development · doi:10.1101/gad.313104 · Cited by 823
Huntly, B. J. P., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, D., Williams, I. R., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.015 · Cited by 697
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia
Somervaille, T. C. P., & Cleary, M. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.020 · Cited by 582
Wunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415
Myeloid Lineage Commitment from the Hematopoietic Stem Cell
Iwasaki, H., & Akashi, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.004 · Cited by 394
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2008-06-163246 · Cited by 384
Self-citationYamanaka, R., Barlow, C., Lekstrom-Himes, J., Castilla, L. H., Liu, P. P., Eckhaus, M., Decker, T., Wynshaw-Boris, A., & Xanthopoulos, K. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13187 · Cited by 383
Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K., Ridler, C., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-10-118331 · Cited by 373
Cited by
Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237
Self-citationMyelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Montalban‐Bravo, G. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187
Saunthararajah, Y. (2013) · Hematology · doi:10.1182/asheducation-2013.1.511 · Cited by 79
Self-citationGu, X., Hu, Z., Ebrahem, Q., Crabb, J. S., Mahfouz, R. Z., Radivoyevitch, T., Crabb, J. W., & Saunthararajah, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562447 · Cited by 42
“Other questions have direct treatment implications: of the hundreds of chromatin regulators that are expressed in hematopoietic cells, the specific subset aberrantly recruited to differentiation-promoting transcription factors in leukemia cells would be logical targets for inhibition to restore terminal differentiatio…”
BackgroundSelf-citation
Metadata
- Authors
- Saunthararajah, Y., Triozzi, P., Rini, B., Singh, A., Radivoyevitch, T., Sekeres, M., Advani, A., Tiu, R., Reu, F., Kalaycio, M., Copelan, E., Hsi, E., Lichtin, A., & Bolwell, B.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 39
- Issue
- 1
- Pages
- 97-108
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W1964227719
- Cited by
- 53
- References
- 40
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. https://app.cochat.ai/papers/10.1053/j.seminoncol.2011.11.011
- The paper
- Saunthararajah, Y., Triozzi, P., Rini, B., Singh, A., Radivoyevitch, T., Sekeres, M., Advani, A., Tiu, R., Reu, F., Kalaycio, M., Copelan, E., Hsi, E., Lichtin, A., & Bolwell, B. (2012). p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. Seminars in Oncology. https://doi.org/10.1053/j.seminoncol.2011.11.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.